Our 2024/2025 ESG report marks a year of progress

We are pleased to announce the release of our ESG report for 2024/2025, which describes our collective progress across environmental sustainability, social responsibility and ethical governance.

Chris Winchester, our Chief Executive Officer, says:

“We are all immensely proud of the strong ethical foundation that underpins everything we do at Oxford PharmaGenesis.

“Our people practise the values that define us, whether through their leadership in shaping industry best practice or their dedication to treating clients, healthcare professionals and patients with care and consideration. The trust placed in us by our clients, partners and communities is something prized by us all.

“This year’s ESG report demonstrates that, in a changing and challenging world, we are doing our bit, not least in our Mission to accelerate adoption of evidence-based innovations for patients in areas of unmet medical need.”

We thank all of our colleagues for their contributions to our strong ESG performance throughout the year.

Find some of our highlights below, or read the full report here.

Environmental highlights

• Our strong environmental performance resulted in another EcoVadis Silver sustainability award and a reduction in our greenhouse gas emissions.
• Our first independent environmental audits confirmed compliance of our environmental management system and greenhouse gas emissions reporting with ISO standards.
• We have received an A grade for our Climate Change and C grade for Water Security for our submissions to CDP.

Social highlights

• More than a quarter of us participated in mentoring programmes.
• Our colleagues’ well being was supported by new flexible working measures.
• We raised £44 000 for charities!
• Our innovation programme Idea Elevator, alongside the growth of the in‑house Copilot Champions community, is strengthening our culture of professional development and ensuring responsible use of AI.

Governance highlights

• We have received Cyber Essentials Plus certification for the sixth consecutive year and our first CyberVadis Silver certificate to reflect our improved score of 816/1000.
• Open Pharma, which we co-fund, launched its AI Discussion Forum to enable its Members and Supporters discuss topics such as best practice for incorporating the use of AI into publishing workflows.
• Many of our colleagues are leaders in professional societies within our industry or their working groups/subcommittees.